Hypertension (high blood pressure) is a common condition in which the force of the blood against the artery walls is high enough that it may eventually cause serious health problems. These health problems include heart attack, stroke, chronic kidney disease and heart failure.
This report provides the current prevalent population for Hypertension across 12 Major Markets (USA, Canada, France, Germany, Russian Federation, Italy, Spain, UK, Japan, China, Brazil and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Hypertension have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Hypertension include:
• Chronic heart failure
• Chronic kidney disease
• Myocardial infarction
• Ischemic heart disease
• Stroke
• Diabetes
• Metabolic syndrome
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Hypertension’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Hypertension and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Hypertension’s prevalent population.
• Identify sub-populations within Hypertension which require treatment.
• Gain an understanding of the specific markets that have the largest number of Hypertension patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key comorbid conditions/Features associated with the disease
• Methodology for quantification of patient numbers
• Top-line prevalence for Hypertension
• Features of Hypertension patients
o BMI Status
o Kidney Function
o CKD Stage
o Hypertension Status
• Comorbidities of Hypertension patients
o Diabetes
o CHF
o CAD
o PAD
o Dyslipidemia
o Elevated CRP
o Metabolic Syndrome
o Retinopathy
o Atrial Fibrillation
o Diagnosed/Aware
• Abbreviations used in the report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
• Hypertension classification
• Prevalence of Hypertension, total (000s)
• Prevalence of Hypertension, males (000s)
• Prevalence of Hypertension, females (000s)
• Hypertension patients by BMI Status, total (000s)
• Hypertension patients by Kidney Function, total (000s)
• Hypertension patients by CKD Stage, total (000s)
• Controlled Hypertension patients, total (000s)
• Uncontrolled Hypertension patients by Stage, total (000s)
• Hypertension patients with Diabetes, total (000s)
• Hypertension patients with CHF, total (000s)
• Hypertension patients with CAD, total (000s)
• Hypertension patients with PAD, total (000s)
• Hypertension patients with Dyslipidemia, total (000s)
• Hypertension patients with Elevated CRP, total (000s)
• Hypertension patients with Metabolic Syndrome, total (000s)
• Hypertension patients with Retinopathy, total (000s)
• Hypertension patients with Atrial Fibrillation, total (000s)
• Diagnosed/Aware Hypertension patients, total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of Hypertension by 5-yr age cohort, males (000s)
• USA Prevalence of Hypertension by 5-yr age cohort, females (000s)
• Canada Prevalence of Hypertension by 5-yr age cohort, males (000s)
• Canada Prevalence of Hypertension by 5-yr age cohort, females (000s)
• France Prevalence of Hypertension by 5-yr age cohort, males (000s)
• France Prevalence of Hypertension by 5-yr age cohort, females (000s)
• Germany Prevalence of Hypertension by 5-yr age cohort, males (000s)
• Germany Prevalence of Hypertension by 5-yr age cohort, females (000s)
• Russian Federation Prevalence of Hypertension by 5-yr age cohort, males (000s)
• Russian Federation Prevalence of Hypertension by 5-yr age cohort, females (000s)
• Italy Prevalence of Hypertension by 5-yr age cohort, males (000s)
• Italy Prevalence of Hypertension by 5-yr age cohort, females (000s)
• Spain Prevalence of Hypertension by 5-yr age cohort, males (000s)
• Spain Prevalence of Hypertension by 5-yr age cohort, females (000s)
• UK Prevalence of Hypertension by 5-yr age cohort, males (000s)
• UK Prevalence of Hypertension by 5-yr age cohort, females (000s)
• Japan Prevalence of Hypertension by 5-yr age cohort, males (000s)
• Japan Prevalence of Hypertension by 5-yr age cohort, females (000s)
• China Prevalence of Hypertension by 5-yr age cohort, males (000s)
• China Prevalence of Hypertension by 5-yr age cohort, females (000s)
• Brazil Prevalence of Hypertension by 5-yr age cohort, males (000s)
• Brazil Prevalence of Hypertension by 5-yr age cohort, females (000s)
• India Prevalence of Hypertension by 5-yr age cohort, males (000s)
• India Prevalence of Hypertension by 5-yr age cohort, females (000s)
